NCT01534312View on ClinicalTrials.gov

Casein Glycomacropeptide in Active Distal Ulcerative Colitis (Pilot Study)

NACompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

September 30, 2014

Study Completion Date

December 31, 2014

Conditions
Colitis, UlcerativeInflammatory Bowel Diseases
Interventions
DRUG

CGMP protein

Casein glycomacropeptide purified powder dissolved in 300 ML water once daily

DRUG

Maximal oral 5ASA

4800 grams/day of Mesalazine (Asacol/Mezavant)

Trial Locations (1)

8000

Department of medicine V (Hepatology and Gastroenterology), Aarhus C

All Listed Sponsors
collaborator

Arla Foods

INDUSTRY

lead

University of Aarhus

OTHER

NCT01534312 - Casein Glycomacropeptide in Active Distal Ulcerative Colitis (Pilot Study) | Biotech Hunter | Biotech Hunter